Compare Incyte Corporation (INCY) vs NetFlix Inc (NFLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs NetFlix Inc — how do they compare? Incyte Corporation trades at $115.81 (market cap $23.44B), while NetFlix Inc trades at $68.56 (market cap $285.94B). The key difference: NetFlix Inc is far larger — about 12.2× Incyte Corporation's market cap, and Incyte Corporation is trading nearer its 52-week high, NetFlix Inc nearer its low. Which is the better fit depends on your goals.
| INCY | NFLX | |
|---|---|---|
Market Cap | $23.44B | $285.94B |
Sector | Health | Consumer Cyclical |
52-Week High | $118.52 | $126.33 |
52-Week Low | $68.90 | $67.60 |
Enterprise Value | $19.46B | $291.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $117.39, up 0.12% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $112.78. The company reported strong Q1 2026 earnings of $1.81 per share, beating expectations, and maintains robust profitability with a net income margin of 26.71%. Recent developments include a collaboration with Halozyme for cancer therapy and positive regulatory updates for Opzelura in Europe.
Outlook remains positive driven by earnings growth and pipeline advancements, though risks include competitive pressures and reliance on key products. The stock offers potential upside to the high target of $140, supported by institutional interest and solid cash flow generation, but investors should monitor execution on upcoming Q2 results.
Netflix (NFLX) trades at $67.6, down 1.96% on the day and near its 52-week low, reflecting a bearish technical trend. Fundamentally, the company shows strong growth with Q1 2026 EPS beating estimates at $1.23 versus $0.763 expected, and revenue reaching $45.18 billion in 2025. Analyst consensus remains bullish with a $90.47 price target, but recent news highlights stock declines amid advertising business expansion.
The outlook for NFLX hinges on scaling its ad-supported tier and live content, offering upside potential, but risks include competitive pressures and market sentiment shifts. With a P/E of 21.26 and robust cash flow, the stock presents a value opportunity if execution aligns with growth projections, though volatility near support levels warrants caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About NetFlix Inc
Netflix Inc. is an Internet subscription service for watching television shows and movies. Subscribers can instantly watch unlimited television shows and movies streamed over the Internet to their televisions, computers, and mobile devices and in the United States, subscribers can receive standard definition DVDs and Blu-ray Discs delivered to their homes.
Read more on NFLX →
